BRCA genes: Lessons learned from experimental and clinical cancer

F. Muggia*, T. Safra, L. Dubeau

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Advances in the study of BRCA1 and BRCA2 gene functions have relied on the development of animal models for seeking to explore further what we have learned from the human disease. Specifically, mouse models of a 'triplenegative' breast cancer (utilizing conditional knockout of BRCA1 and p53 in the breast), of an endometrioid ovarian cancer (based on oncogenic kras and loss of function of pten), and of anatomic and functional consequences of BRCA1 mutations in granulosa cells, have led to further inquiry into the pathogenesis and therapeutic consequences of genetic alterations. A striking susceptibility of these murine malignancies to platinum drugs has emerged, providing further confidence in their relevance to the human disease. In addition to these models, the pathogenesis of highgrade serous disease derived from risk-reducing surgeries in mutation carriers has pointed to a role of mutations in p53 commonly encountered in tubal intraepithelial carcinomas.

Original languageEnglish
Pages (from-to)i7-i10
JournalAnnals of Oncology
Volume22
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Keywords

  • BRCA1
  • BRCA2
  • Cisplatin
  • Endometrioid
  • Granulosa cell
  • Kras
  • Ovarian
  • PTEN
  • Serous
  • Stem cells
  • p53

Fingerprint

Dive into the research topics of 'BRCA genes: Lessons learned from experimental and clinical cancer'. Together they form a unique fingerprint.

Cite this